ELSI Friday Forum: Public-Private Partnerships for Gene Therapies: What does the Public Get?

Publicly-funded researchers frequently transfer their gene therapy and gene-editing medical research to venture capital-funded startups for clinical development. In tandem, the public sector financial crisis in many countries has meant that partnerships with commercial entities are used to leverage the full potential of publicly-held genomic data. However, public-private partnerships in the genomics translational pipeline raise several key questions. Which benefits should be returned to the public, if any? How should products be priced? How should data be managed? Does involvement of publicly funded scientists in the commercial sector conflict with the commitment to deliver societally beneficial innovation?

Panelists: John Conley, JD, PhD & Eva Winkler, Prof, Dr.med., Dr.phil. Moderator: Philip J. Brooks, PhD.